Symon Cotton has been reflecting on the future of the genomics ecosystem. Here he discusses how genomics – plus the emergence of panomics and long read sequencing – could inform clinical practice and patient care.
Not everyone knows how to embark on the road to a new market breakthrough – or has the confidence to overcome natural hesitancy. At CC, we believe in the design thinking approach known as DVF (Desirability, Viability, Feasibility).
Swiss company Qnami, a leader in quantum sensing technology, tasked us with identifying potential applications in the biomedical area where NV magnetometry could provide clinical value and open new commercial avenues.
The world of DNA testing is changing fast and the race is on to provide cheap, quick genetic diagnoses for patients. Symon Cotton, Head of Life Sciences takes a look at the opportunities on offer for companies working in this dynamic field.
Cell4D is developing ‘fingerprinting’ technology for live cells using mechanomics, a discipline sitting at the intersection of biology and biomechanics. This biomarker that is used to screen and sort live cells for cell therapies.
Global pharma is hitting a major fork in the road, and one way leads to failure. For me, it’s vital that the industry comes together to grasp the once-in-a-generation opportunity that emergent technology is offering.